ACT-660602 (Idorsia Pharmaceuticals) is an oral chemokine receptor CXCR3 antagonist being developed for autoimmune diseases. Chemokines and their receptors make up the signaling system that is responsible for immune cell migration. This is important for the innate immune system’s ability for fighting infection, but dysregulation of [...]
3 minute read
Sep. 28, 2022
ACT-660602: an Oral Chemokine Receptor CXCR3 Antagonist for Autoimmune Diseases
ACT-660602
oral CXCR3 antagonist efficacy in mice model of lung inflammation from HTS and opt J. Med. Chem. Idorsia Pharmaceuticals Ltd., Allschwil, CH